Skip to main content

Table 2 Utility, observed and predicted, for all patients with complete questionnaires (n = 1905)

From: Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model

 

Mean utility

SD

Min.

Max.

RMSE

MAE

Spearman correlation

p-value

Observed utility (Dutch tariff)

0.834

0.171

−0.134

1

-

-

-

-

Observed utility (U.K. tariff)

0.803

0.197

− 0.239

1

-

-

-

-

Predicted utility (Versteegh (6))

0.866

0.135

−0.298

0.978

0.113

0.080

0.76

< 0.001*

Predicted utility (Longworth (7) (Dutch tariff)

0.835

0.127

−0.088

0.959

0.106

0.078

0.77

0.687*

Predicted utility (Longworth (7) (U.K. tariff)

0.810

0.152

−0.307

0.955

0.114

0.085

0.79

0.026**

Predicted utility (Marriott (9))

0.813

0.185

−0.159

1.061

0.122

0.089

0.75

0.001**

  1. *p-value tested against Dutch tariff ** p-value tested against U.K. tariff; p-values result from a t-test